M7920
Minoxidil Sulfate
K+ channel opener, powder
Synonym(s):
U-58838
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H15N5O4S
CAS Number:
Molecular Weight:
289.31
UNSPSC Code:
12352107
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Minoxidil Sulfate,
SMILES string
Nc1cc(nc(N)[n+]1OS([O-])(=O)=O)N2CCCCC2
InChI
1S/C9H15N5O4S/c10-7-6-8(13-4-2-1-3-5-13)12-9(11)14(7)18-19(15,16)17/h6H,1-5H2,(H4,10,11,12,15,16,17)
InChI key
OEOLOEUAGSPDLT-UHFFFAOYSA-N
form
powder
originator
Johnson & Johnson
storage temp.
−20°C
Quality Level
Related Categories
Application
Minoxidil sulfate (MXS) has been used as a drug agent to study its effects on alopecia in corticotropin-releasing factor over-expressing (CRF-OE) mice. It has also been used as a positive control in an assay for the culturing of rat vibrissa follicles.
Biochem/physiol Actions
Minoxidil sulfate (MXS) is an endogenous derivative of minoxidil. It possesses greater aqueous solubility and is a potent vasodilator. MXS has the potential to treat androgenic alopecia or male baldness.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Other Notes
Active metabolite of minoxidil.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
K D Meisheri et al.
The Journal of pharmacology and experimental therapeutics, 266(2), 655-665 (1993-08-01)
This study describes the in vitro and in vivo characteristics of a guanidine 4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexyl-hydroc hloride (U-37883A), as an antagonist of vascular ATP-sensitive K+ channels (KATP). In isolated rabbit mesenteric artery, the antagonistic effects of U-37883A (0.5-5 microM) were studied against
Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception?
G J Mulder
Trends in pharmacological sciences, 13(8), 302-304 (1992-08-01)
Nagendra S Ningaraj et al.
Cancer research, 63(24), 8899-8911 (2003-12-26)
Brain tumor microvessels/capillaries limit drug delivery to tumors by forming a blood-brain tumor barrier (BTB). The BTB overexpresses ATP-sensitive potassium (K(ATP)) channels that are barely detectable in normal brain capillaries, and which were targeted for BTB permeability modulation. In a
Michael J Shackcloth et al.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 34(4), 839-844 (2008-08-06)
Vasodilator strategies used to treat bypass grafts in the operating theatre, such as nitrates, phosphodiesterase inhibitors and calcium channel antagonists have a broad but short-lived effect against a variety of vasoconstrictor stimuli. Treatments that react irreversibly with proteins modulating vasoconstriction
C E Ohrnberger et al.
The Journal of pharmacology and experimental therapeutics, 267(1), 25-30 (1993-10-01)
Glyburide, a sulfonylurea, and U-37883A, a guanidine (4-Morpholinecarboximidine-N-1-Adamantyl-N' cyclohexylhydrochloride), have been previously characterized as antagonists of the vascular ATP-sensitive K+ channels (KATP). In this report, the in vitro interaction between these two chemically distinct KATP antagonists was investigated using isolated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service